
Thermo Fisher Scientific
About
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
Sector Focus
Healthcare
Drug Discovery
Clinical Development
Biomarkers
Target Discovery
Combination Selection
Indication Expansion
Drug Development
Pharmaceuticals
Biotech
Series Focus
Series B
Portfolio
Investment Activity
No timeline data for this period
Score Breakdown
28Deal Activity
15Track Record
10Visibility
17Profile
85Community
0Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What type of investor is Thermo Fisher Scientific?
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics…
What kind of firm is Thermo Fisher Scientific?
Thermo Fisher Scientific is a Company.
Where is Thermo Fisher Scientific based?
Thermo Fisher Scientific is based in United States.
What sectors does Thermo Fisher Scientific focus on?
Thermo Fisher Scientific focuses on Healthcare, Drug Discovery, Clinical Development, Biomarkers.
Similar Investors